Zevra Therapeutics, Inc. Common Stock ZVRA
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-07T01:13:15.977Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:43:40.355714026Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-07T01:13:15.571276+00:00
Zevra Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 12.31 | 83.6% | 11.6% | |||
| 40Δ | 12.14 | 89.8% | 10.8% | |||
| 45Δ | 11.94 | 94.3% | 10.0% | |||
| 50Δ | 11.68 | 92.5% | 8.6% | |||
| 55Δ | 11.42 | 90.7% | 7.2% | |||
| 60Δ | 11.15 | 88.9% | 5.8% | |||
| 65Δ | 10.90 | 86.8% | 4.7% | |||
| 70Δ | 10.66 | 84.2% | 3.8% | 13.43 | 123.0% | 3.9% |
| 75Δ | 10.42 | 81.6% | 3.0% | 14.32 | 139.1% | 3.4% |
| 80Δ | 10.18 | 79.0% | 2.1% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 12.31
- IV
- 83.6%
- B/E move
- 11.6%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 12.14
- IV
- 89.8%
- B/E move
- 10.8%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 11.94
- IV
- 94.3%
- B/E move
- 10.0%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 11.68
- IV
- 92.5%
- B/E move
- 8.6%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 11.42
- IV
- 90.7%
- B/E move
- 7.2%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 11.15
- IV
- 88.9%
- B/E move
- 5.8%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 10.90
- IV
- 86.8%
- B/E move
- 4.7%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 10.66
- IV
- 84.2%
- B/E move
- 3.8%
- Pseudo strike
- 13.43
- IV
- 123.0%
- B/E move
- 3.9%
75Δ
- Pseudo strike
- 10.42
- IV
- 81.6%
- B/E move
- 3.0%
- Pseudo strike
- 14.32
- IV
- 139.1%
- B/E move
- 3.4%
80Δ
- Pseudo strike
- 10.18
- IV
- 79.0%
- B/E move
- 2.1%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 92.94% | |
| 86.10% | |
| 87.86% | |
| 91.80% | |
| 94.66% | |
| 89.17% | |
| 108.49% | |
| 76.57% | |
| 79.38% | |
| 84.43% |
Biotechnology
ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in…
More →AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the…
More →ABCL
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
More →ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in…
More →ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative…
More →ABSI
Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes a proprietary AI-driven platform to revolutionize drug discovery and development. By facilitating the rapid…
More →